| Literature DB >> 35163417 |
Luciano C Ramires1, Gabriel Silva Santos2, Rafaela Pereira Ramires3, Lucas Furtado da Fonseca4, Madhan Jeyaraman5, Sathish Muthu6, Anna Vitória Lana7, Gabriel Azzini2, Curtis Scott Smith8, José Fábio Lana2.
Abstract
Some say that all diseases begin in the gut. Interestingly, this concept is actually quite old, since it is attributed to the Ancient Greek physician Hippocrates, who proposed the hypothesis nearly 2500 years ago. The continuous breakthroughs in modern medicine have transformed our classic understanding of the gastrointestinal tract (GIT) and human health. Although the gut microbiota (GMB) has proven to be a core component of human health under standard metabolic conditions, there is now also a strong link connecting the composition and function of the GMB to the development of numerous diseases, especially the ones of musculoskeletal nature. The symbiotic microbes that reside in the gastrointestinal tract are very sensitive to biochemical stimuli and may respond in many different ways depending on the nature of these biological signals. Certain variables such as nutrition and physical modulation can either enhance or disrupt the equilibrium between the various species of gut microbes. In fact, fat-rich diets can cause dysbiosis, which decreases the number of protective bacteria and compromises the integrity of the epithelial barrier in the GIT. Overgrowth of pathogenic microbes then release higher quantities of toxic metabolites into the circulatory system, especially the pro-inflammatory cytokines detected in osteoarthritis (OA), thereby promoting inflammation and the initiation of many disease processes throughout the body. Although many studies link OA with GMB perturbations, further research is still needed.Entities:
Keywords: gut microbiota; metabolic syndrome; osteoarthritis; systemic inflammation
Mesh:
Year: 2022 PMID: 35163417 PMCID: PMC8835947 DOI: 10.3390/ijms23031494
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Mechanism of regulation of immune response by gut microbiome. The native immune system is tolerant to the resident gut microbiome under the tight control of intestinal epithelial cells using mucosal barrier, secretory IgA and antimicrobial peptides (AMP). The native gut microbiome stimulates the intestinal epithelial cells, dendritic cells and macrophages to activate the T regulatory (T reg) cells and T helper 17 (Th17) cells. Upon activation of the intestinal epithelial cells with toll-like receptors (TLRs), B-cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are secreted which promotes the differentiation of IgA producing plasma cells, whereas in dysbiotic status of gut microbiome with the loss of barrier integrity and breach in the intestinal epithelial cell barrier, translocation of bacterial components, pathogen-associated molecular patterns (PAMPs), intestinal immune system is triggered through TLR activation. This results in an inflammatory cascade through hyperactivation of T helper 1 (Th1) and Th17 cells resulting in section of inflammatory cytokines.
Figure 2Interventional strategies to counteract dysbiotic gut microbiome.
Common types of prebiotics and their functions.
| Prebiotics | Functions |
|---|---|
| Fructans | Selectively stimulates lactic acid bacteria. |
| Galacto-Oligosaccharides | Stimulates |
| Starch and Glucose-Derived Oligosaccharides | Elevates butyrate production and stimulates |
| Other Oligosaccharides (pectin-derived) | Strengthens the mucus layer, enhances epithelial integrity, and activates or inhibits immune cells. |
| Non-Starch Oligosaccharides (flavonoids) | Inhibits the growth of pathogens, increases the number of Bifidobacterium and Lactobacillus, reduces endotoxin production, converts bile acids, maintains gut homeostasis, and promotes nutrient absorption. |
Figure 3Challenges in Fecal Microbiota Transplantation (FMT) therapy.
Figure 4Traditional phage therapy for gut dysbiosis with pathogenic microbiome.